Review Article
The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism
Table 2
The effects of Nrf2 activators in rodent models of NAFLD or NASH.
| Nrf2 activator | Species | Administration route | Reported effect | Reference |
| CDDO-Im | Mouse | Oral | Prevented HFD-induced increases in body weight, adipose mass, and hepatic lipid accumulation | [24] | CDDO-Me | Mouse | Oral | Reduced hepatic lipid accumulation, proinflammatory cytokine expression, and lipogenic gene expression in mice fed HFD | [26] | Sulforaphane | Mouse | Intraperitoneal | Attenuated hepatic fibrosis induced by bile duct ligation | [27] | Sulforaphane | Mouse | Oral | Suppressed oxidative stress and hepatic fibrosis induced by MCD diet | [28] | Oltipraz, NK-252 | Rat | Oral | Attenuated hepatic fibrosis induced by CDAA diet | [29] |
|
|
CDAA, choline-deficient L-amino acid-defined diet; CDDO-Im, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; CDDO-Me, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]methyl; HFD, high-fat diet; MCD, methionine- and choline-deficient diet.
|